Evaluation of Vectrine (R) efficacy and safety versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion.

The clinical efficacy of vectrine(R) (erdosteine) was evaluated in the trea tment of chronic bronchitis patients with hypersecretion during a controlle d clinical trial having included 170 patients. For inclusion, the bronchiti s patients had to be in a stable status (no exacerbation since at least thr ee months). The patients received, in double-blind protocol, vectrine(R), o ne capsule b.i.d. or placebo, one similar capsule b.i.d. during a period tr eatment of 21 days. The results of the main evaluation criteria, the global index of efficacy frequency of the cough + severity of the cough + difficu lty in breathing + dyspnea) but also on the intensity and frequency of the cough were statistically Significant in favor of vectrine(R). The safety of the treatment was excellent.